Gsk Dividends - GSK

Stock Name	Stock Symbol	Market	Stock Type
Gsk Plc	GSK	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	12.20	0.85%	1,439.60	16:35:16

Open Price	Low Price	High Price	Close Price	Previous Close
1,421.80	1,416.40	1,451.60	1,439.60	1,427.40

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Gsk GSK Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
27/07/2022	1	GBX	16.25	31/12/2021	31/12/2022	18/08/2022	19/08/2022	06/10/2022	0
27/04/2022	1	GBX	14	31/12/2021	31/12/2022	19/05/2022	20/05/2022	01/07/2022	0
09/02/2022	Final	GBX	23	31/12/2020	31/12/2021	24/02/2022	25/02/2022	07/04/2022	80
27/10/2021	1	GBX	19	31/12/2020	31/12/2021	18/11/2021	19/11/2021	13/01/2022	0
28/07/2021	1	GBX	19	31/12/2020	31/12/2021	19/08/2021	20/08/2021	07/10/2021	0
28/04/2021	1	GBX	19	31/12/2020	31/12/2021	20/05/2021	21/05/2021	08/07/2021	0
03/02/2021	Final	GBX	23	31/12/2019	31/12/2020	18/02/2021	19/02/2021	08/04/2021	80
28/10/2020	1	GBX	19	31/12/2019	31/12/2020	12/11/2020	13/11/2020	14/01/2021	0
29/07/2020	1	GBX	19	31/12/2019	31/12/2020	13/08/2020	14/08/2020	08/10/2020	0
29/04/2020	1	GBX	19	31/12/2019	31/12/2020	14/05/2020	15/05/2020	09/07/2020	0
05/02/2020	Final	GBX	23	31/12/2018	31/12/2019	20/02/2020	21/02/2020	09/04/2020	80
30/10/2019	1	GBX	19	31/12/2018	31/12/2019	14/11/2019	15/11/2019	09/01/2020	0
24/07/2019	1	GBX	19	31/12/2018	31/12/2019	08/08/2019	09/08/2019	10/10/2019	0
01/05/2019	1	GBX	19	31/12/2018	31/12/2019	16/05/2019	17/05/2019	11/07/2019	0
06/02/2019	Final	GBX	23	31/12/2017	31/12/2018	21/02/2019	22/02/2019	11/04/2019	80
31/10/2018	1	GBX	19	31/12/2017	31/12/2018	15/11/2018	16/11/2018	10/01/2019	0
25/07/2018	1	GBX	19	31/12/2017	31/12/2018	09/08/2018	10/08/2018	11/10/2018	0
25/04/2018	1	GBX	19	31/12/2017	31/12/2018	10/05/2018	11/05/2018	12/07/2018	0
07/02/2018	Final	GBX	23	31/12/2016	31/12/2017	22/02/2018	23/02/2018	12/04/2018	80
25/10/2017	1	GBX	19	31/12/2016	31/12/2017	09/11/2017	10/11/2017	11/01/2018	0
26/07/2017	1	GBX	19	31/12/2016	31/12/2017	10/08/2017	11/08/2017	12/10/2017	0
26/04/2017	1	GBX	19	31/12/2016	31/12/2017	11/05/2017	12/05/2017	13/07/2017	0
08/02/2017	Final	GBX	23	31/12/2015	31/12/2016	23/02/2017	24/02/2017	13/04/2017	80
26/10/2016	1	GBX	19	31/12/2015	31/12/2016	03/11/2016	04/11/2016	12/01/2017	0
27/07/2016	1	GBX	19	31/12/2015	31/12/2016	11/08/2016	12/08/2016	13/10/2016	0
27/04/2016	1	GBX	19	31/12/2015	31/12/2016	12/05/2016	13/05/2016	14/07/2016	0
03/02/2016	Special	GBX	20	31/12/2014	31/12/2015	18/02/2016	19/02/2016	14/04/2016	0
03/02/2016	Final	GBX	23	31/12/2014	31/12/2015	18/02/2016	19/02/2016	14/04/2016	100
19/10/2015	1	GBX	19	31/12/2014	31/12/2015	12/11/2015	13/11/2015	14/01/2016	0
29/07/2015	1	GBX	19	31/12/2014	31/12/2015	13/08/2015	14/08/2015	01/10/2015	0
06/05/2015	1	GBX	19	31/12/2014	31/12/2015	14/05/2015	15/05/2015	09/07/2015	0
04/02/2015	Final	GBX	23	31/12/2013	31/12/2014	19/02/2015	20/02/2015	09/04/2015	80
22/10/2014	1	GBX	19	31/12/2013	31/12/2014	06/11/2014	07/11/2014	08/01/2015	0
24/07/2014	1	GBX	19	31/12/2013	31/12/2014	06/08/2014	08/08/2014	02/10/2014	0
30/04/2014	1	GBX	19	31/12/2013	31/12/2014	14/05/2014	16/05/2014	10/07/2014	0
05/02/2014	Final	GBX	23	31/12/2012	31/12/2013	19/02/2014	21/02/2014	10/04/2014	78
23/10/2013	1	GBX	19	31/12/2012	31/12/2013	13/11/2013	15/11/2013	09/01/2014	0
24/07/2013	1	GBX	18	31/12/2012	31/12/2013	07/08/2013	09/08/2013	03/10/2013	0
24/04/2013	1	GBX	18	31/12/2012	31/12/2013	08/05/2013	10/05/2013	11/07/2013	0
06/02/2013	Final	GBX	22	31/12/2011	31/12/2012	20/02/2013	22/02/2013	11/04/2013	74
31/10/2012	1	GBX	18	31/12/2011	31/12/2012	14/11/2012	16/11/2012	03/01/2013	0
25/07/2012	1	GBX	17	31/12/2011	31/12/2012	08/08/2012	10/08/2012	04/10/2012	0
25/04/2012	1	GBX	17	31/12/2011	31/12/2012	09/05/2012	11/05/2012	05/07/2012	0
07/02/2012	Final	GBX	21	31/12/2010	31/12/2011	15/02/2012	17/02/2012	12/04/2012	75
07/02/2012	Special	GBX	5	31/12/2010	31/12/2011	15/02/2012	17/02/2012	12/04/2012	0
26/10/2011	Interim	GBX	17	31/12/2010	31/12/2011	02/11/2011	04/11/2011	05/01/2012	0
26/07/2011	Interim	GBX	16	31/12/2010	31/12/2011	03/08/2011	05/08/2011	06/10/2011	0
27/04/2011	Interim	GBX	16	31/12/2010	31/12/2011	04/05/2011	06/05/2011	07/07/2011	0
03/02/2011	Final	GBX	19	31/12/2009	31/12/2010	09/02/2011	11/02/2011	07/04/2011	65
21/10/2010	Interim	GBX	16	31/12/2009	31/12/2010	27/10/2010	29/10/2010	06/01/2011	0
21/07/2010	Interim	GBX	15	31/12/2009	31/12/2010	28/07/2010	30/07/2010	07/10/2010	0
28/04/2010	Interim	GBX	15	31/12/2009	31/12/2010	05/05/2010	07/05/2010	08/07/2010	0
04/02/2010	Final	GBX	18	31/12/2008	31/12/2009	10/02/2010	12/02/2010	08/04/2010	61
29/10/2009	1	GBX	15	31/12/2008	31/12/2009	04/11/2009	06/09/2009	07/01/2010	0
30/07/2009	1	GBX	14	31/12/2008	31/12/2009	31/07/2009	31/07/2009	08/10/2009	28
22/04/2009	1	GBX	14	31/12/2008	31/12/2009	29/04/2009	01/05/2009	09/07/2009	0
05/02/2009	Final	GBX	17	31/12/2007	31/12/2008	11/02/2009	13/02/2009	09/04/2009	57
22/10/2008	1	GBX	14	31/12/2007	31/12/2008	29/10/2008	31/10/2008	09/01/2008	0
07/02/2008	Final	GBX	13	31/12/2006	31/12/2007	13/02/2008	15/02/2008	10/04/2008	53
25/07/2007	1	GBX	12	31/12/2006	31/12/2007	01/08/2007	03/08/2007	11/10/2007	0
24/04/2007	1	GBX	12	31/12/2006	31/12/2007	02/05/2007	04/05/2007	12/07/2007	0
08/02/2007	1	GBX	14	31/12/2005	31/12/2006	14/02/2006	16/02/2006	12/04/2007	0
08/02/2007	Final	GBX	0	31/12/2005	31/12/2006	01/01/1970	01/01/1970	01/01/1970	48
26/10/2006	1	GBX	12	31/12/2005	31/12/2006	01/11/2006	03/11/2006	04/01/2007	0
26/07/2006	1	GBX	11	31/12/2005	31/12/2006	02/08/2006	04/08/2006	05/10/2006	0
27/04/2006	1	GBX	11	31/12/2005	31/12/2006	10/05/2006	12/05/2006	06/07/2006	0
08/02/2006	Final	GBX	14	31/12/2004	31/12/2005	15/02/2006	17/02/2006	06/04/2006	44
27/10/2005	1	GBX	10	31/12/2004	31/12/2005	02/11/2005	04/11/2005	05/01/2006	0
29/07/2005	1	GBX	10	31/12/2004	31/12/2005	03/08/2005	05/08/2005	06/10/2005	0
28/04/2005	1	GBX	10	31/12/2004	31/12/2005	11/05/2005	13/05/2005	07/07/2005	0
10/02/2005	Final	GBX	12	31/12/2003	31/12/2004	16/02/2005	18/02/2005	07/04/2005	42
28/10/2004	1	GBX	10	31/12/2003	31/12/2004	03/11/2004	05/11/2004	06/01/2005	0
27/07/2004	1	GBX	10	31/12/2003	31/12/2004	12/05/2004	14/05/2004	01/07/2004	0
27/07/2004	1	GBX	10	31/12/2003	31/12/2004	04/08/2004	06/08/2004	30/09/2004	0
12/02/2004	Final	GBX	14	31/12/2002	31/12/2003	18/02/2004	20/02/2004	15/04/2004	41
11/02/2004	1	GBX	9	31/12/2002	31/12/2003	29/10/2003	31/10/2003	06/01/2004	0
23/07/2003	1	GBX	9	31/12/2002	31/12/2003	30/07/2003	01/08/2003	02/10/2003	0
30/04/2003	1	GBX	9	31/12/2002	31/12/2003	07/05/2003	09/05/2003	03/07/2003	0
12/02/2003	Final	GBX	13	31/12/2001	31/12/2002	19/02/2003	21/02/2003	17/04/2003	40
23/10/2002	1	GBX	9	30/03/2002	30/09/2002	30/10/2002	01/11/2002	03/01/2003	0
24/07/2002	1	GBX	9	30/12/2001	30/06/2002	31/07/2002	02/08/2002	03/10/2002	0
25/04/2002	1	GBX	9	01/10/2001	31/03/2002	01/05/2002	03/05/2002	04/07/2002	0
14/02/2002	Final	GBX	12	31/12/2000	31/12/2001	20/02/2002	22/02/2002	18/04/2002	39
23/10/2001	1	GBX	9	30/09/2000	30/09/2001	31/10/2001	02/11/2001	03/01/2002	0
24/07/2001	1	GBX	9	30/06/2000	30/06/2001	01/08/2001	03/08/2001	04/10/2001	0
24/04/2001	1	GBX	9	31/03/2000	31/03/2001	02/05/2001	04/05/2001	05/07/2001	0
13/12/2000	Final	GBX	23	31/12/1999	31/12/2000	18/12/2000	22/12/2000	17/04/2001	38
27/07/2000	Interim	GBX	15	30/12/1999	30/06/2000	07/08/2000	11/08/2000	16/10/2000	0
16/02/2000	Final	GBX	22	31/12/1998	31/12/1999	28/02/2000	03/03/2000	25/05/2000	37
29/07/1999	Interim	GBX	15	30/12/1998	30/06/1999	09/08/1999	13/08/1999	01/10/1999	0
18/02/1999	Final	GBX	21	31/12/1997	31/12/1998	01/03/1999	05/03/1999	20/05/1999	36

Top Dividend Posts

Top Posts
Posted at 02/2/2023 10:01 by tradermichael How is all this getting 'missed' by investors? Even before GSK's corporate reshaping, which culminated with last summer's Haleon spinoff, the company has long held a leading presence in the HIV field via its ViiV Healthcare joint venture. Within the HIV franchise, GSK's new long-acting injectable therapy Cabenuva started to come into its own in 2022. The drug generated 340 million pounds last year, a sizable jump from 38 million pounds in 2021, when it won its initial FDA approval in January of that year. Also, Apretude, the company’s long-acting HIV prevention drug, has seen “very strong” demand after its approval in late 2021, Walmsley said Wednesday. Its sales totaled 41 million pounds in 2022. Like Cabenuva, GSK says it has negotiated favorable coverage for the drug in the U.S., so the company expects the launch to continue to gain steam in 2023. Also, Vaccines are another major financial driver for the company. GSK's star vaccine, Shingrix for shingles, suffered from a pandemic slowdown in 2020 and 2021, but the product is rolling once again. Riding a “post-pandemic rebound,” Shingrix delivered a record year in 2022, Chief Commercial Officer Luke Miels said a recent call. Sales reached 2.9 billion pounds last year, a whopping 60% increase from 2021. Also, GSK is also anticipating another big vaccine launch this year. The drugmaker submitted its respiratory syncytial virus vaccine candidate to regulators in the U.S., Europe and Japan. The shot is expected to become a blockbuster and vie for market share in this new arena against players such as Pfizer, Sanofi and Moderna. Read Full Thread Follow Reply
Posted at 11/1/2023 10:15 by geckotheglorious Some may be interested. ”GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference” hTTps://seekingalpha.com/article/4569061-gsk-plc-gsk-presents-41st-annual-jpmorgan-healthcare-conference-transcript? There is an option to listen to the pitch as well (Press Play Earnings Call button) Read Full Thread Follow Reply
Posted at 05/12/2022 16:10 by geckotheglorious Bilster1 last week. GSK is a potential buyout candidate for Novartis - Intron Health” GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London. The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology. In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal. Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025. The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition. hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis? Read Full Thread Follow Reply
Posted at 05/12/2022 14:55 by geckotheglorious The ADRs of GSK plc (NYSE:GSK) dropped ~1% pre-market Monday after Bank of America downgraded its shares to Underperform from Neutral, arguing that the British drugmaker remains the firm’s least preferred name among the European majors. Despite an “undemanding” PE multiple for 2024, “we see insufficient catalysts to rerate (GSK) shares near-term,” the analysts led by Graham Parry wrote, slashing their price target on the stock to 1450p from 1640p. Noting the ~ £4B free cash flow the company generates, the analysts expect claims related to heartburn medication Zantac to weigh on GSK shares which, according to the analysts, more than discount their base case $4B liability risk. Despite encouraging Phase 3 data, the analysts see no reason for GSK’s RSV vaccine to outcompete a rival shot from Pfizer (PFE). They also point out that the company has indicated a slower ramp for the RSV vaccine compared to its shingles vaccine Shingrix given the need to educate the public/physicians on the disease. “While encouraged by GSK’s strong RSV vaccine PIII data we view Pfizer’s vaccine as credible competition given little to no perceived differentiation on efficacy and worse reactogenicity (tolerability) for GSK,” the team wrote. They also argue that the company’s key franchises remain under pressure and a weak pipeline is unlikely to avoid an upcoming patent cliff in 2028/29E for HIV medication dolutegravir made worse by recent setbacks, including the recall of blood cancer therapy Blenrep. hTTps://seekingalpha.com/news/3913915-gsk-cut-to-underperform-at-bank-of-america-says-least-preferred-european-major? Read Full Thread Follow Reply
Posted at 30/11/2022 20:22 by geckotheglorious ”GSK is a potential buyout candidate for Novartis - Intron Health” GSK (NYSE:GSK) could be a potential buyout target for Novartis (NYSE:NVS) (OTCPK:NVSEF) as the Swiss pharma company is eyeing a large acquisition, Bloomberg reported Wednesday, citing Intron Health, an Equity Research firm based in London. The analyst Naresh Chouhan argues that a potential combination with GSK (GSK) will enable Novartis (NVS) to re-enter the vaccine market and virology in a bid to diversify its business away from the competitive and risky oncology. In 2015, Novartis (NVS) divested its global vaccine business (excluding influenza vaccines) to GSK (GSK), then known as GlaxoSmithKline, after a $5.25B deal. Even with a 40% premium, the analyst projects that such a deal could be over 40% accretive after three years, assuming $2B synergies and a 6% cost of debt. A cash-based deal will lower proforma net debt to 2.4x EBITDA by 2025. The analyst notes that the “temporary mispricing” of GSK (GSK) stock due to financial overhang from Zantac claims has paved the way for an “opportunistic” acquisition. hTTps://seekingalpha.com/news/3912660-gsk-stock-gains-on-buyout-claims-linked-to-novartis? Read Full Thread Follow Reply
Posted at 11/11/2022 14:42 by geckotheglorious GSK drops as UBS cuts to Sell on 2027 “bottleneck” GSK (NYSE:GSK) lost ~4% pre-market Friday after UBS downgraded the British drugmaker to Sell from Hold, questioning the durability of the company’s HIV franchise and revenue from its shingles vaccine Shingrix beyond 2027. The analysts led by Michael Leuchten estimate a ~20% revenue hit to the company when Shingrix reaches the peak penetration in the U.S. catch-up population in 2027 and HIV therapy dolutegravir faces a patent cliff around the same timeframe. The analysts think the current consensus for GSK (GSK) fails to recognize the uncertainty over the HIV franchise and implies more than £2B Shingrix revenue than feasible. The company has time to adjust R&D options and earmark additional capital (£20B – £30B) to tide over the 2027 “bottleneck,” but “this could mean earnings dilution,” the team added, lowering the 12-month price target on GSK (GSK) to 1,300p from 1,820p. hTTps://seekingalpha.com/news/3906392-gsk-drops-as-ubs-cuts-to-sell-on-2027-bottleneck? Read Full Thread Follow Reply
Posted at 03/11/2022 09:06 by stewart64 I wasn't a holder of GSK on demerger day, so didn't go into the mechanics at that time. But wondered if someone can answer this query please. I understand that 5 shares in old GSK became 4 shares in new GSK. Yet Haleon is worth considerably more than one quarter of new GSK. Therefore why didn't the price of new GSK go down on demerger day? Or did the price adjustment occur later and by what factor. As I'm assuming comparing the old and new GSK price isn't comparing like with like? Read Full Thread Follow Reply
Posted at 02/11/2022 10:24 by tradermichael Zantac The Zantac litigation continues in federal and state courts in the United States. GSK's position on the scientific validity of these cases has not changed since the last reporting period. GSK will continue to defend all claims vigorously. GSK has been named as a co-defendant in approximately 4,100 filed personal injury cases in federal and state court. There are approximately 77,000 plaintiffs named in these cases. A significant majority of these plaintiffs were named in a series of multi-plaintiff complaints recently filed in Delaware state court and most of these plaintiffs were previously in the Multidistrict Litigation (MDL) Census Registry in the Southern District of Florida. They were removed because they allege a cancer other than the 5 cancers being pursued by the MDL plaintiffs. In the MDL, plaintiffs originally identified 10 different types of cancers they wished to pursue. Plaintiffs subsequently dropped 5 of the 10 cancers, and they are proceeding only as to bladder, esophageal, gastric, liver, and pancreatic, although plaintiffs in state courts continue to pursue claims beyond the 5 designated cancers. There are approximately 33,000 unfiled claims relating to GSK and other co-defendants concerning the 5 designated cancers in the MDL Census Registry. There are also over 2,000 California state court cases subject to an agreement between GSK and the plaintiffs which suspends the statute of limitations to allow the plaintiffs to bring their claims at a later date. These filed and unfiled counts are subject to change. As planned, in September and October 2022, the MDL Court held hearings on the admissibility of each side's general causation expert witnesses ("Daubert hearings"). Based on the 12 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any type of cancer. The 12th additional epidemiologic study (Wang et al. (2022)) was recently released. When comparing ranitidine to an active comparator (famotidine), Wang 2022 found a statistically significant increased risk with regard to liver cancer (Hazard Ratio 1.22, 95% Confidence Interval 1.06-1.40) and no statistically significant increased risk for the remaining 4 cancers pursued in the MDL. Consistency across available epidemiological evidence, particularly where reported potential associations are modest, is critical for drawing reliable conclusions about causation. The parties await a decision from Judge Robin L. Rosenberg. In the California Zantac litigation Cases JCCP 5150 (JCCP), the Court will hold a Sargon hearing on 25 January 2023 regarding the admissibility of expert witnesses, including general causation expert witnesses, for the first bellwether trials. The first bellwether trial is expected to start on 13 February 2023 in the California JCCP. The Illinois Supreme Court recently consolidated all Illinois ranitidine cases in Cook County for pretrial proceedings with trial dates to be set, including the previously scheduled Madison County trial. Given the complex ownership and marketing of Zantac prescription and over-the-counter (OTC) medicine over many years, numerous claims involve several defendants. As a result, some defendants have served one another, including GSK, with notice of potential indemnification claims about possible liabilities connected particularly with Zantac OTC. Given the early stage of the proceedings, GSK cannot meaningfully assess what liability, if any, it may have, nor can it meaningfully assess the liability of other parties under relevant indemnification provisions. Further information regarding the litigation can be found in GSK's 11 August 2022 and 16 August 2022 statements. Read Full Thread Follow Reply
Posted at 02/11/2022 08:44 by tradermichael Don't forget OLD GSK = New GSK + HLN. Then understand that for Haleon, analysts estimate an annual dividend of six pence a share in 2023 and seven pence in 2024. So longer term holders can add that to their GSK dividend income .... ;0) Read Full Thread Follow Reply
Posted at 13/10/2022 07:01 by tradermichael Yes spyder, truly exceptional results: GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial -- Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile -- Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%) -- High vaccine efficacy is consistent across RSV A and B strains GSK plc (LSE/NYSE: GSK) today announced positive pivotal phase III trial results for its respiratory syncytial virus (RSV) vaccine candidate for adults aged 60 years and above to be presented at IDWeek 2022. The vaccine candidate was highly efficacious, demonstrating overall vaccine efficacy of 82.6% (96.95% CI, 57.9-94.1, 7 of 12,466 vs. 40 of 12,494) against RSV lower respiratory tract disease (RSV-LRTD), meeting the trial's primary endpoint. Consistent high vaccine efficacy was also observed across a range of pre-specified secondary endpoints, highlighting the impact the vaccine candidate could have on the populations most at risk of the severe outcomes of RSV. Efficacy against severe RSV-LRTD, defined as LRTD with at least two lower respiratory signs or assessed as severe by the investigator and confirmed by the external adjudication committee, was 94.1% (95% CI, 62.4-99.9, 1 of 12,466 vs. 17 of 12,494). In participants with pre-existing comorbidities, such as underlying cardiorespiratory and endocrinometabolic conditions, vaccine efficacy was 94.6% (95% CI, 65.9-99.9, 1 of 4,937 vs. 18 of 4,861), with 93.8% (95% CI, 60.2-99.9, 1 of 4,487 vs. 16 of 4,487) efficacy observed in adults aged 70-79 years. Vaccine efficacy against LRTD was consistent across both RSV-A and RSV-B subtypes (84.6%; CI 32.1-98.3, 2 of 12,466 vs. 13 of 12,494 and 80.9%; CI 49.4-94.3, 5 of 12,466 vs. 26 of 12,494 respectively), consistent with the robust neutralising antibody response generated against both subtypes. See Figure 1: Vaccine efficacy against first episodes of RSV-confirmed LRTD and RSV-confirmed ARI (modified exposed set). Tony Wood, GSK Chief Scientific Officer, said: "These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research. We believe that with the high vaccine efficacy demonstrated in this pivotal trial, our vaccine candidate has the potential to help reduce the significant global burden of RSV-associated disease in older adults, including those at the greatest risk of severe outcomes due to their age or underlying comorbidities." The vaccine was well tolerated with a favourable safety profile. The observed solicited adverse events were typically mild-to-moderate and transient, the most frequent being injection site pain, fatigue, myalgia, and headache. Regulatory submissions based on the phase III data are anticipated in the second half of 2022. GSK's RSV vaccine candidate for older adults contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK's proprietary AS01(E) adjuvant. There are currently no RSV vaccines approved anywhere in the world. Read Full Thread Follow Reply

Your Recent History

LSE

GSK

Gsk

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20230205 10:23:59